DISEASE ACTIVITY, ANCA AND IL23R GENOTYPE STATUS DETERMINE EARLY RESPONSE TO INFLIXIMAB IN PATIENTS WITH ULCERATIVE COLITIS

(1) University Hospital Munich-Grosshadern, Department of Medicine II

(2) Institute for Medical Informatics, Biometry and Epidemiology (IBE), Ludwig-Maximilians-University Munich, Munich

(3) Department of Paediatrics, Medical School Hannover, Hannover, Germany



This item was part of the Anti TNF therapy in IBD: Current to future session at Gastro 2009 UEGW/WCOG London (17th UEGW)

This item can be cited as: Gut 2009; 58 (Suppl II) A69